Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder

NCT00746681

Last updated date
Study Location
Pfizer Investigational Site
Hradec Kralove, , 500 05, Czech Republic
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Overactive Bladder
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Women > 18 years Old

- Diagnosis of OAB (micturition frequency >/= 8 times per day; urinary urgency >/= 4 times per week)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects with symptoms of overactive bladder for less than 6 months prior to
randomization.


- Significant stress incontinence as determined by the investigator e.g. stress
predominant mixed incontinence, positive cough provocation test.


- Subjects with any condition that would contraindicate the use of tolterodine or
pregabalin, including: Uncontrolled narrow angle glaucoma; Urinary retention;
Myasthenia gravis; Gastric retention; Severe ulcerative colitis; Toxic megacolon; Rare
hereditary problems of galactose intolerance; Fructose intolerance; Sucrose-isomalate
insufficiency; Lapp lactase deficiency; Glucose-galactose malabsorption.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Overactive BladderFesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children
NCT02327936
ALL GENDERS
5 Years+
years
MULTIPLE SITES
Overactive BladderExtension Study of Fesoterodine for Overactive Bladder Syndrome in Children.
NCT02614482
  1. Québec City, Quebec
ALL GENDERS
5 Years+
years
MULTIPLE SITES
Overactive BladderInterventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder
NCT01515722
  1. Seoul,
  2. Daegu,
  3. Changwon,
  4. Seoul,
  5. Bucheon,
  6. Seoul,
  7. Bucheon,
  8. Seoul,
  9. Seoul,
  10. Pusan,
  11. Gwangju,
  12. Deajeon,
  13. Seoul,
Female
18 Years+
years
MULTIPLE SITES
Overactive BladderFall Prevention in Older Adults With OAB
NCT03946124
Female
65 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder
Official Title  ICMJE A Phase 2, 26 Week, Multicentre, Randomized Double Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Tolterodine, Pregabalin and a Tolterodine-Pregabalin Combination for Idiopathic Overactive Bladder
Brief Summary Tolterodine is approved for use in the treatment of overactive bladder (OAB). The study is designed to a investigate whether pregabalin may have efficacy in OAB and whether the efficacy is altered when it is combined with tolterodine.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Overactive Bladder
Intervention  ICMJE
  • Drug: Tolterodine & Pregabalin
    Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
  • Drug: Tolterodine
    Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
  • Drug: Placebo
    Placebo, Oral, twice daily for 4 weeks
  • Drug: Tolterodine & Pregabalin
    Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
  • Drug: Pregabalin
    Pregabalin, Oral, 150 mg twice daily for 4 weeks
Study Arms  ICMJE
  • Experimental: A
    Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily
    Intervention: Drug: Tolterodine & Pregabalin
  • Active Comparator: B
    Tolterodine SR 4 mg once daily
    Intervention: Drug: Tolterodine
  • Placebo Comparator: C
    Placebo
    Intervention: Drug: Placebo
  • Experimental: D
    Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily
    Intervention: Drug: Tolterodine & Pregabalin
  • Experimental: E
    Pregabalin 150 mg twice daily
    Intervention: Drug: Pregabalin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 3, 2008)
188
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE November 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Women > 18 years Old
  • Diagnosis of OAB (micturition frequency >/= 8 times per day; urinary urgency >/= 4 times per week)

Exclusion Criteria:

  • Subjects with symptoms of overactive bladder for less than 6 months prior to randomization.
  • Significant stress incontinence as determined by the investigator e.g. stress predominant mixed incontinence, positive cough provocation test.
  • Subjects with any condition that would contraindicate the use of tolterodine or pregabalin, including: Uncontrolled narrow angle glaucoma; Urinary retention; Myasthenia gravis; Gastric retention; Severe ulcerative colitis; Toxic megacolon; Rare hereditary problems of galactose intolerance; Fructose intolerance; Sucrose-isomalate insufficiency; Lapp lactase deficiency; Glucose-galactose malabsorption.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Czech Republic,   Lithuania,   Norway,   Slovakia,   Sweden,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00746681
Other Study ID Numbers  ICMJE A8881001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP